Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 120.38M | 100.40M | 94.20M | 71.93M | 67.95M |
Gross Profit | 104.05M | 87.69M | 86.53M | 67.75M | 64.10M |
EBITDA | -899.49M | -892.00M | -692.00M | -471.00M | -411.23M |
Net Income | -904.80M | -1.10B | -787.00M | -599.02M | -413.22M |
Balance Sheet | |||||
Total Assets | 1.82B | 1.69B | 2.57B | 3.30B | 1.12B |
Cash, Cash Equivalents and Short-Term Investments | 1.67B | 1.54B | 2.44B | 3.21B | 1.07B |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 386.43M | 295.46M | 170.10M | 148.38M | 34.91M |
Stockholders Equity | 1.43B | 1.40B | 2.40B | 3.15B | 1.08B |
Cash Flow | |||||
Free Cash Flow | -794.64M | -992.87M | -734.82M | -510.71M | -425.66M |
Operating Cash Flow | -719.49M | -833.90M | -564.27M | -476.84M | -422.84M |
Investing Cash Flow | -75.16M | -150.34M | -212.99M | -33.87M | -2.82M |
Financing Cash Flow | 923.38M | 63.94M | -20.00K | 2.65B | 1.01B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
83 Outperform | $2.24T | 12.09 | 13.71% | 2.25% | 4.04% | 21.20% | |
75 Outperform | $1.35T | 35.31 | 4.61% | 2.28% | 3.62% | -59.69% | |
68 Neutral | ¥6.86T | 23.31 | 18.32% | 1.63% | 14.09% | 31.96% | |
65 Neutral | $491.05B | 25.98 | 10.94% | ― | 26.28% | ― | |
65 Neutral | ¥352.42B | 10.85 | -2.99% | 2.46% | 11.67% | -10.31% | |
56 Neutral | $26.12B | ― | -193.61% | ― | 179.79% | -204.13% | |
42 Neutral | ¥6.00B | ― | ― | 16.18% | 31.67% |
Perseus Proteomics Inc. announced its business forecasts for the fiscal year ending March 31, 2025, with a focus on licensing agreements for its pipeline projects PPMX-T002 and PPMX-T003. The company anticipates significant R&D and administrative expenses, impacting its financial results. Despite challenges in forecasting due to incomplete licensing activities, Perseus Proteomics remains committed to maximizing the value of its projects, which could influence its market positioning and stakeholder interests.
Perseus Proteomics Inc. announced the completion of a clinical study report for its Phase I trial of PPMX-T003, an anti-transferrin receptor 1 antibody, in patients with polycythemia vera. The trial, which involved six subjects, demonstrated safety and indicated efficacy, with five subjects experiencing a 12-week period without the need for phlebotomy. The results have no impact on the company’s fiscal year 2025/3 business results.
Perseus Proteomics Inc. has announced an amendment regarding its PPMX-T003 project, which is part of a drug discovery support program for orphan drugs. The amendment clarifies that the research group led by Dr. Ai Kotani at Osaka University, rather than Osaka Metropolitan University, has identified PPMX-T003 as a potential therapeutic drug for ANKL. This correction may impact stakeholders’ understanding of the project’s progress and the company’s collaboration with academic institutions.
Perseus Proteomics Inc. announced that its drug candidate, PPMX-T003, intended for treating aggressive NK cell leukemia, has been selected for the Drug Discovery Support Program for Orphan drugs by Japan’s AMED. This selection supports the ongoing clinical trials, which have been extended by a year, and provides a subsidy of 100 million yen to aid in trial expenses, potentially impacting the company’s financial forecast for FY2026/3.
Perseus Proteomics Inc. reported non-operating income, expenses, and extraordinary losses in the first nine months of the fiscal year ending March 2025. The company experienced gains from foreign exchange, outsourcing services, and interest, but also incurred costs related to capital increase and share issuance. A significant impairment loss on non-current assets was recorded, impacting the financial results for the third quarter, as announced.
Perseus Proteomics Inc. reported its financial results for the nine months ending December 31, 2024, showing a small increase in net sales by 15.9% compared to the previous year. Despite this, the company continues to experience financial losses, with a net loss recorded. The financial position showed an increase in total assets and net assets, but the company refrained from providing a forecast for the fiscal year ending March 31, 2025, citing difficulties in making rational predictions.